Wet Cupping Therapy in Ankylosing Spondylitis

September 16, 2026 updated by: SULEYMAN ERSOY, Karabuk University

Wet Cupping Therapy in Ankylosing Spondylitis: a Multicenter Quasi- Randomised Controlled Trial

This study evaluates the efficacy of wet cupping therapy in patients with ankylosing spondylitis.Wet cupping therapy will be applied to half of the patients plus routine pharmaceutical treatment while the other half will receive only pharmaceutics

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

In addition to the medical treatment, WCT will be applied once every 28 days , 3 times (Day 0, 28, 56) to the intervention group whereas the control group will not receive any intervention. The BASFI, BASDAI, CRP, FFD, VAS and Modified Schober (MSI) tests will be applied to both groups at 0 and 3 months.

Study Type

Interventional

Enrollment (Actual)

109

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age between 18-65 years
  • Confirmed diagnosis of ankylosing spondylitis (AS) according to the modified New York criteria or the ASAS classification criteria for axial spondyloarthritis
  • Active disease at enrolment, confirmed by a PM&R specialist
  • Written informed consent and compliance with the study protocol

Exclusion Criteria:

  • Having received WCT within the previous 3 months
  • Contraindications to WCT (hemoglobin <9.5 g/dL, known bleeding or coagulation disorders, anticoagulant use or antiplatelet therapy other than aspirin <100 mg, INR >1.5, etc.)
  • Pregnancy or breastfeeding
  • Severe uncontrolled comorbidities (e.g., advanced cardiovascular disease, uncontrolled diabetes, active malignancy, severe psychiatric illness)
  • Any change in AS medication during the study period
  • Failure to complete either baseline or follow-up visits

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Wet cupping arm

This arm is the interventiom group and will receive three consecutive sessions of wet cupping therapy once a month.

wet cupping therapy will be applied to participants in this arm for three sessions once a month

No Intervention: Control arm

This arm is the control group and will not receive any intervention other than the routine medications

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
BASDAI
Time Frame: At 0 and 9th weeks

Change in the scores of The Bath Ankylosing Spondylitis Disease Activity Index

At 0 and 9th weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Schober
Time Frame: At 0 and 9th weeks

Change in the scores of Modified Schober Test

At 0 and 9th weeks
BASFI
Time Frame: At 0 and 9th weeks

Change in the scores of The Bath Ankylosing Spondylitis Functional Index

At 0 and 9th weeks
VAS
Time Frame: At 0 and 9th weeks

Change in the scores of Visual Analogue Scale

At 0 and 9th weeks
C Reactive Protein (CRP)
Time Frame: At 0 and 9th weeks

Changes in the values of CRP

At 0 and 9th weeks
fingertip-to-floor distance (FFD),
Time Frame: 0 th and 9 th weeks

Changes in the values of fingertip-to-floor distance (FFD),

0 th and 9 th weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2024

Primary Completion (Actual)

October 1, 2025

Study Completion (Actual)

October 30, 2025

Study Registration Dates

First Submitted

March 7, 2023

First Submitted That Met QC Criteria

March 18, 2023

First Posted (Actual)

March 31, 2023

Study Record Updates

Last Update Posted (Actual)

September 21, 2026

Last Update Submitted That Met QC Criteria

September 16, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • SBU177

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.